IMPROVE EYE HEALTH

WITH LACRISERT®

PRODUCT DESCRIPTION:
This medication is an insert that is placed in your eye to treat dry eyes. It is usually used when an artificial tears
solution is not successful. This medication may also be used to treat certain other eye disorders (keratitis, decreased
corneal sensitivity). It works by keeping the eye moist, helping to protect the eye from injury and infection and to
decrease symptoms of dry eyes such as burning, itching, and feeling as if something is in the eye.

DOSAGE
One LACRISERT® ophthalmic insert in each eye once daily is usually
sufficient to relieve the symptoms associated with moderate to severe dry
eye syndromes. Individual patients may require more flexibility in the use
of LACRISERT®; some patients may require twice daily use for optimal
results.
Clinical experience with LACRISERT® indicates that in some patients
several weeks may be required before satisfactory improvement of
symptoms is achieved.

INDICATION AND USE

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is an insert
placed in your eye to treat moderate to severe dry eyes. It also can be
used to treat the following eye conditions: exposure keratitis, decreased
corneal sensitivity and recurrent corneal erosions.

ROUTE OF ADMINISTRATION
LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is a sterile,
translucent, rod-shaped, water soluble, ophthalmic insert made of
hydroxypropyl cellulose, for administration into the inferior cul-de-sac of
the eye.

SIMPLE STEPS IN APPLYING

LACRISERT® EFFECTIVELY:
Wash your hands thoroughly with soap and running water.
Rinse the soft and flexible applicator with hot water. Shake off the excess.
Pick up the LACRISERT® insert by lightly touching it with the grooved tip
of the applicator.

POCKET
Gently grasp the outer corner of the lower eyelid between your thumb and
index finger and pull out to create a “pocket.”

PLACE
Place the LACRISERT® insert by gently brushing it on the inside of the
“pocket.”

PULL UP AND OVER

Pull the lower lid up and over the LACRISERT® insert, then release. Allow
the insert to settle comfortably in the “pocket.”

APPLICATION TIPS
• Add a drop or two of artificial tears after placement to expedite softening
• Put contact lens in first, then place LACRISERT®
• If using makeup, put makeup on first, then place LACRISERT®
• LACRISERT® may be used at night or in the morning

LEARN MORE ABOUT LACRISERT® AT LACRISERT.COM/ECP

 Encountering
menopausal problems?

Be in the
pink of health

PRODUCT DESCRIPTION:
ESTRING® is a slightly opaque, soft, flexible vaginal ring with a
center that contains 2 mg of estradiol (an estrogen hormone). It
releases estradiol into the vagina in a consistent, stable manner
for 90 days. Estring is indicated for the treatment of moderate-to-
severe symptoms of vulvar and vaginal atrophy due to
menopause.

DOSAGE
One ESTRING® (estradiol vaginal ring) is to be inserted as deeply
as possible into the upper onethird of the vaginal vault. The ring is
to remain in place continuously for three months, after which it is
to be removed and, if appropriate, replaced by a new ring. The
need to continue treatment should be assessed at 3 or 6 month
intervals.
Should the ring be removed or fall out at any time during the 90-
day treatment period, the ring should be rinsed in lukewarm water
and re-inserted by the patient, or, if necessary, by a physician or
nurse.

INDICATION AND USE

ESTRING® (estradiol vaginal ring) is an estrogen indicated for the
treatment of moderate to severe urogenital symptoms due to
postmenopausal atrophy of the vagina (such as dryness, burning,
pruritus and dyspareunia) and/or the lower urinary tract (urinary
urgency and dysuria).

ROUTE OF ADMINISTRATION
The ring should be pressed into an oval and inserted into the
upper third of the vaginal vault. The exact position is not
critical.

INSTRUCTION FOR USE

ESTRING® can be inserted and removed by you or your doctor or healthcare provider. To insert
ESTRING yourself, choose the position that is most comfortable for you: standing with one leg up,
squatting, or lying down.

After washing and drying your hands,

remove ESTRING from its pouch using Hold ESTRING between your thumb Gently push the compressed ring into Once inserted, keep the vaginal ring in
the tear-off notch on the side. (Since the and index finger and press the opposite your vagina as far as you can up towards place as long as directed by your
ring becomes slippery when wet, be sure sides of the ring together as shown. your cervix. healthcare provider.
your hands are dry before handling it.)

ESTRING® is a local estrogen therapy used after menopause to treat moderate to severe menopausal
changes in and around the vagina.
ESTRING PROVIDES RELIEF OF LOCAL SYMPTOMS OF MENOPAUSE ONLY.
Patients should always ask their doctors for medical advice about adverse events.

Find more information on ESTRING® at https://www.estring.com/

 HEALTH FOR HIM

HOW'S YOUR
PROSTATE?
Up close and personal with prostate cancer and subdermal implant
treatment Zoladex®.
Information sourced from https://www.zoladexhcp.com/prostate-cancer/

PRODUCT INFORMATION
Zoladex® is indicated for use in combination with
flutamide for the management of locally confined
Stage T2b-T4 (Stage B2-C) carcinoma of the prostate.
Treatment with Zoladex® and flutamide should start 8
weeks prior to initiating radiation therapy and continue
during radiation therapy.

Zoladex® is also indicated for use in the palliative

treatment of advanced carcinoma of the prostate. For
the management of advanced prostate cancer,
Zoladex® is intended for long-term administration
unless clinically inappropriate.

DOSAGE ROUTE OF ADMINISTRATION

Each Zoladex® injection contains 3.6 mg of goserelin.
It also contains lactide‑glycolidecopolymer which is
an inactive substance.
STAGE B2-C PROSTATIC CARCINOMA
When Zoladex® is given in combination with
radiotherapy and flutamide for patients with Stage T2b-
T4 (Stage B2-C) prostatic carcinoma, treatment should
be started 8 weeks prior to initiating radiotherapy and
should continue during radiation therapy. A treatment
regimen using a Zoladex® 3.6 mg depot 8 weeks
before radiotherapy, followed in 28 days by the
Zoladex® 10.8 mg depot, can be administered.
Alternatively, four injections of 3.6 mg depot can be
administered at 28-day intervals, two depots preceding
and two during radiotherapy.
Zoladex®, at a dose of 3.6 mg, should be administered
subcutaneously every 28 days into the anterior abdominal
wall below the navel line using an aseptic technique under
the supervision of a physician.
INDICATION
STAGE B2-C PROSTATIC CARCINOMA
Zoladex® is indicated for use in combination with flutamide
for the management of locally confined Stage T2b-T4
(Stage B2-C) carcinoma of the prostate.
Treatment with Zoladex® and flutamide should start 8
weeks prior to initiating radiation therapy and continue
during radiation therapy

PROSTATIC CARCINOMA PROSTATIC CARCINOMA

For the management of advanced prostate cancer, Zoladex® is indicated in the palliative treatment of
Zoladex® is intended for long-term administration advanced carcinoma of the prostate
unless clinically inappropriate.

GUIDE IN USING ZOLADEX®

CLEAN THE INJECTION-SITE AREA INSPECT THE SYRINGE

Clean an area of the anterior abdominal wall
(below the navel) for injection using an
alcohol swab.
Inspect the foil pouch and syringe for
damage. Remove the syringe from the
pouch and hold it at a slight angle to make
sure part of the implant is visible. Remove
the plastic safety tab and needle cover.

PINCH THE SKIN INSERT THE NEEDLE

Pinch the patient’s skin using aseptic
technique at the prepared injection site, and
hold the needle with the bevel facing up at
an injection angle of 30°-45°
Note: Extra care should be taken with
patients with low BMI and/or patients
receiving a full dose of anticoagulation.
Insert the needle, with the bevel facing up,
until the protective sleeve touches the
patient’s skin. Take care not to penetrate the
muscle or peritoneum.
Note: If the needle penetrates a large blood
vessel, blood will immediately be seen in the
syringe chamber. If this occurs, withdraw the
needle and inject a new syringe at a new
location. Monitor patients for signs of
abdominal hemorrhage.

DEPRESS THE PLUNGER WITHDRAW THE NEEDLE

Depress the plunger until you hear a “CLICK.” Withdraw the needle and allow the protective
The click ensures the SafeSystem has been sleeve to slide and cover the needle; dispose
activated and the implant has been deposited in an approved sharps container.
in the correct location.

For more resources about your prostate health, seek advice from a
urologist or urologic oncologist near you.
 Making a
Convenient
Choice
Norplant is a subdermal implant providing contraceptive
protection over a five-year period, empowering women worldwide
to make an independent choice for their reproductive health.

Product Description
The Norplant subdermal implant is a low-dose,
progestogen-only method of contraception that
is long-acting, highly effective and reversible. It
consists of six matchstick-sized, flexible, Silastic
capsules, which are usually implanted under the
medial surface of the non-dominant upper arm.
These release a sustained low dose of levonorgestrel
into the system at the levels needed to achieve
effective contraception. The dose gradually decreases
over a five-year period, after which time its
contraceptive efficacy starts to diminish.

Dosage
The NORPLANT SYSTEM consists of six Silastic®
capsules, each containing 36 mg of the progestin,
levonorgestrel. The total administered (implanted)
dose is 216 mg.

Indication
The NORPLANT SYSTEM is indicated for the
prevention of pregnancy and is a long-term (up to 5
years) reversible contraceptive system. The capsules
should be removed by the end of the 5th year. New
capsules may be inserted at that time if continuing
contraceptive protection is desired.

INSERTION INSTRUCTIONS:

Use the scalpel to make a small

Prepare Equipment:
Sterile surgical drapes, sterile
gloves (free of talc), antiseptic
solution.local anesthetic,
needles, and syringe.
#11 scalpel, #10 trocar, forceps.
skin closure, sterile gauze, and
compresses.
Have the patient lie on her
back on the examination
table with her left arm
flexed at the elbow and
externally rotated so that
her hand is lying by her
head.
Prep the patient's upper arm
with antiseptic solution; cover
the arm above and below the
insertion area with a sterile
cloth. The optimal insertion
area is in the inside of the upper
arm about 8 to 10 cm above the
elbow crease.
Open the sterile NORPLANT
SYSTEM package carefully
by pulling apart the sheets
of the pouch, allowing the
capsules to fall onto a sterile
drape. Count the six
capsules.
Open the sterile NORPLANT
SYSTEM package carefully
by pulling apart the sheets
of the pouch, allowing the
capsules to fall onto a sterile
drape. Count the six
capsules.
incision (about 2 mm) just through
the dermis of the skin.
Alternatively, the trocar may be
inserted directly through the skin
without making an incision with
the scalpel. The bevel of the trocar
should always face up during the
insertion.

Insert the tip of the trocar through

The trocar has two marks on it.
The first mark is closer to the hub
and indicates how far the trocar
should be introduced under the
skin before the loading of each
capsule. The second mark is close
to the tip and indicates how much
of the trocar should remain under
the skin following the insertion of
each implant.
the incision beneath the skin at a
shallow angle. Once the trocar is
inserted, it should be oriented with
the bevel up toward the skin to keep
the capsules in a superficial plane. It
is important to keep the trocar
subdermal by tenting the skin with
The capsule should have been
the trocar, as failure to do so may
result in deep placement of the
Hold the obturator steady, released under the skin when
capsules and could make removal When the trocar has been Gently advance the capsule and bring the trocar back the mark close to the tip of the
more difficult.Advance the trocar inserted the appropriate with the obturator towards until it touches the handle of trocar is visible in the incision.
gently under the skin to the first distance, remove the the tip of the trocar until the obturator. Release of the capsule can be
mark near the hub of the trocar. The obturator and load the first you feel resistance. Never
checked by palpation. It is
tip of the trocar is now at a distance
of about 4 to 4.5 cm from the
capsule into the trocar using force the obturator. important to keep the obturator
incision. the thumb and forefinger. steady and not to push the
capsule into the tissue.

Do not remove the trocar from the

incision until all capsules have been
inserted. The trocar is withdrawn
only to the mark close to its tip. Each
succeeding capsule is always inserted
next to the previous one, to form a
fanlike shape. Fix the position of the
previous capsule with the forefinger
and middle finger of the free hand,
and advance the trocar along the tips
of the fingers. This will ensure a
suitable distance of about 15 degrees
between capsules and keep the trocar
from puncturing any of the
previously inserted capsules.
After placement of the sixth
Press the edges of the Cover the insertion area
capsule, a sterile gauze may
incision together, and close with a dry compress, and
be used to apply pressure
the incision with a skin wrap gauze around the arm
briefly to the insertion site
closure. Suturing the to ensure hemostasis.
to ensure hemostasis.
incision should not be
Palpate the distal ends of the
necessary.
capsules to make sure that
all six have been properly
placed.

Before you decide to use NORPLANT (levonorgestrel implants (unavailable in us)) or any other birth control method,
compare it to other birth control methods. If you want to learn more about other methods, ask your health-care
professional. One of these other methods may be better for you than NORPLANT.

WARNING: This product is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and
other sexually transmitted diseases (STDs) such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and
syphilis.
With MitraClip™ therapy, your heart-related problems
are now an answered prayer.